バルガンシクロビル市場(用途:臓器移植、サイトメガロウイルス網膜炎) - 世界の産業分析、サイズ、シェア、成長、トレンド、および予測、2022-2031年Valganciclovir Market (Application: Organ Transplant and Cytomegalovirus Retinitis) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 バルガンシクロビル市場 - レポートの範囲 TMRの調査レポート「世界のバルガンシクロビル市場」は、2022年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成... もっと見る
サマリーバルガンシクロビル市場 - レポートの範囲TMRの調査レポート「世界のバルガンシクロビル市場」は、2022年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2021年を基準年、2031年を予測年として考慮し、2017年から2031年の期間における世界のバルガンシクロビル市場の収益を提供します。また、2022年から2031年までの世界のバルガンシクロビル市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行った。二次調査では、バルガンシクロビル市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照しました。 二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、世界のバルガンシクロビル市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチを組み合わせたアプローチを採用しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界のバルガンシクロビル市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界のバルガンシクロビル市場への参入に関心のある企業にとっても貴重なツールになります。 本レポートでは、世界のバルガンシクロビル市場の競争環境について掘り下げています。世界のバルガンシクロビル市場で活動する主要企業が特定され、これらの各企業は様々な属性の観点からプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のバルガンシクロビル市場のプレーヤーの属性です。 研究方法論 調査方法は、徹底的な一次調査と二次調査を組み合わせて、バルガンシクロビルの市場を分析します。 二次調査 二次調査には、企業の文献、技術文書、特許データ、インターネット上の情報源、政府ウェブサイト、業界団体、機関などの統計データなどの検索が含まれます。これは、正確なデータを入手し、業界関係者の洞察を得て、ビジネスチャンスを認識するための最も信頼性が高く、効果的で成功した方法であることが証明されています。 一般的に参照する二次研究資料ですが、これらに限定されるものではありません: 企業ウェブサイト、プレゼンテーション、アニュアルレポート、ホワイトペーパー、テクニカルペーパー、製品パンフレット 社内外の独自データベースや関連特許の紹介 各国政府資料、統計データベース、マーケットレポートなど 市場に参入している企業に特化したニュース記事、プレスリリース、ウェブキャストを配信しています。 具体的な二次資料 業界の情報源 WorldWideScience.org エルゼビア社(Elsevier, Inc. 米国国立衛生研究所(NIH) パブコメ エヌシーバイ ヘルスケアサービス部門 貿易データソース トレードマップ 国連コムトレード トレードアトラス 会社情報 OneSource Business Browser フーバーの ファクティバ ブルームバーグ M&A(合併・買収 トムソン M&A マーチャースタット 深遠 一次調査 調査期間中、幅広い業界関係者やオピニオンリーダーとの綿密なインタビューやディスカッションを実施しました。調査の大部分は一次調査であり、二次調査によって補完されています。 データおよび分析の検証のため、業界関係者やコメンテーターへの一次インタビューを継続的に実施しています。典型的なリサーチ・インタビューは、以下のような機能を果たしています: 市場規模、市場動向、成長トレンド、競争環境、展望などに関する生の情報を提供します。 二次調査結果の検証・強化に役立つ 分析チームの専門知識と市場理解のさらなる発展 地域ごとの市場、カテゴリー、セグメント、サブセグメントについて、電子メールでのやりとり、電話取材、対面取材を含むプライマリーリサーチを実施。 このようなプロセスに通常参加する参加者は、これらに限定されるものではありません: 業界関係者の方マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャー、リージョナルセールスマネージャー 購買・調達担当者、技術担当者、販売代理店 外部の専門家:投資銀行、バリュエーション専門家、特定市場に特化したリサーチ・アナリスト 各業界に対応した各分野の専門家であるキーオピニオンリーダー。 主な参加者のリスト(ただし、これらに限定されない): アドバンスト・オンコセラピーPLC Danfysik A/S 株式会社日立製作所 IBA ワールドワイド メビオンメディカルシステムズ株式会社 データの三角測量:二次資料・一次資料」から抽出された情報は、四半期ごとに更新される「TMR Knowledge Repository」と照合されます。 市場推定:市場規模の推定には、製品の特徴、技術の更新、地理的存在、製品の需要、販売データ(金額または数量)、過去の前年比成長率などの詳細な調査が含まれます。また、市場規模や予測を導き出すために、他のアプローチも活用した。ハードデータがない場合は、包括的なデータセットを作成するためにモデリング技法を採用した。厳密な方法論を採用し、入手可能なハードデータと以下のデータタイプを相互参照し、推定値を作成した: 人口動態データ:医療費支出、インフレ率、その他 産業指標研究開発投資、技術段階、インフラ、部門成長、設備など 市場予測:市場の促進要因、阻害要因/課題、機会を考慮し、他のセグメント/サブセグメントに対するメリット/デメリットを考慮した上で、様々なセグメントの市場予測を行います。ビジネス環境、過去の販売パターン、アンメットニーズ、競争力、国別の手術データなども、市場予測を導き出すために考慮される重要な要素のひとつです。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Valganciclovir Market 4. Market Overview 4.1. Introduction 4.1.1. Patient Age Group 4.1.2. Overview 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.3. Global Valganciclovir Market Analysis and Forecast, 2017–2031 4.3.1. Global Valganciclovir Market Revenue Projection (US$ Mn) 5. Market Outlook 5.1. Valganciclovir Virus Disease Prevalence 5.2. Key Industry Development 5.3. COVID-19 Impact Analysis 6. Global Valganciclovir Market Analysis and Forecast, by Patient Age Group 6.1. Key Findings/Developments 6.2. Introduction & Definition 6.3. Global Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 6.3.1. Adult Patients 6.3.2. Pediatric Patients 6.4. Global Valganciclovir Market Attractiveness Analysis, by Patient Age Group 7. Global Valganciclovir Market Analysis and Forecast, by Application 7.1. Key Findings/Developments 7.2. Introduction & Definition 7.3. Global Valganciclovir Market Value Forecast, by Application, 2017–2031 7.3.1. Organ Transplant 7.3.2. Cytomegalovirus Retinitis 7.4. Global Valganciclovir Market Attractiveness Analysis, by Application 8. Global Valganciclovir Market Analysis and Forecast, by Distribution Channel 8.1. Key Findings/Developments 8.2. Introduction & Definition 8.3. Global Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.4. Global Valganciclovir Market Attractiveness Analysis, by Distribution Channel 9. Global Valganciclovir Market Analysis and Forecast, by Region 9.1. Geographical Representation 9.2. Global Valganciclovir Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Global Valganciclovir Market Attractiveness Analysis, by Region 10. North America Valganciclovir Market Analysis and Forecast 10.1. North America Valganciclovir Market Value Share Analysis, by Country, 2017–2031 10.2. North America Valganciclovir Market Value Forecast, by Country, 2017–2031 10.2.1. U.S. 10.2.2. Canada 10.3. North America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 10.4. North America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 10.4.1. Adult Patients 10.4.2. Pediatric Patients 10.5. North America Valganciclovir Market Value Share Analysis, by Application, 2021–2031 10.6. North America Valganciclovir Market Value Forecast, by Application, 2017–2031 10.6.1. Organ Transplant 10.6.2. Cytomegalovirus Retinitis 10.7. North America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 10.8. North America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 10.8.1. Hospital Pharmacies 10.8.2. Retail Pharmacies 10.9. North America Valganciclovir Market Attractiveness Analysis (2022–2031) 10.9.1. By Country 10.9.2. By Patient Age Group 10.9.3. By Application 10.9.4. By Distribution Channel 11. Europe Valganciclovir Market Analysis and Forecast 11.1. Europe Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 11.1.1. Germany 11.1.2. France 11.1.3. U.K. 11.1.4. Spain 11.1.5. Italy 11.1.6. Rest of Europe 11.2. Europe Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 11.3. Europe Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 11.3.1. Adult Patients 11.3.2. Pediatric Patients 11.4. Europe Valganciclovir Market Value Share Analysis, by Application, 2021–2031 11.5. Europe Valganciclovir Market Value Forecast, by Application, 2017–2031 11.5.1. Organ Transplant 11.5.2. Cytomegalovirus Retinitis 11.6. Europe Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 11.7. Europe Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 11.7.1. Hospital Pharmacies 11.7.2. Retail Pharmacies 11.8. Europe Valganciclovir Market Attractiveness Analysis (2022–2031) 11.8.1. By Country/Sub-region 11.8.2. By Patient Age Group 11.8.3. By Application 11.8.4. By Distribution Channel 12. Asia Pacific Valganciclovir Market Analysis and Forecast 12.1. Asia Pacific Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 12.1.1. China 12.1.2. Japan 12.1.3. India 12.1.4. Australia & New Zealand 12.1.5. Rest of Asia Pacific 12.2. Asia Pacific Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 12.3. Asia Pacific Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 12.3.1. Adult Patients 12.3.2. Pediatric Patients 12.4. Asia Pacific Valganciclovir Market Value Share Analysis, by Application, 2021–2031 12.5. Asia Pacific Valganciclovir Market Value Forecast, by Application, 2017–2031 12.5.1. Organ Transplant 12.5.2. Cytomegalovirus Retinitis 12.6. Asia Pacific Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 12.7. Asia Pacific Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 12.7.1. Hospital Pharmacies 12.7.2. Retail Pharmacies 12.8. Asia Pacific Valganciclovir Market Attractiveness Analysis (2022–2031) 12.8.1. By Country/Sub-region 12.8.2. By Patient Age Group 12.8.3. By Application 12.8.4. By Distribution Channel 13. Latin America Valganciclovir Market Analysis and Forecast 13.1. Latin America Valganciclovir Market Value Forecast, by Country/Sub-region, 2017-2027 13.1.1. Brazil 13.1.2. Mexico 13.1.3. Rest of Latin America 13.2. Latin America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 13.3. Latin America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 13.3.1. Adult Patients 13.3.2. Pediatric Patients 13.4. Latin America Valganciclovir Market Value Share Analysis, by Application, 2021–2031 13.5. Latin America Valganciclovir Market Value Forecast, by Application, 2017–2031 13.5.1. Organ Transplant 13.5.2. Cytomegalovirus Retinitis 13.6. Latin America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 13.7. Latin America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 13.7.1. Hospital Pharmacies 13.8. Latin America Valganciclovir Market Attractiveness Analysis (2022–2031) 13.8.1. By Country/Sub-region 13.8.2. By Patient Age Group 13.8.3. By Application 13.8.4. By Distribution Channel 14. Middle East & Africa Valganciclovir Market Analysis and Forecast 14.1. Middle East & Africa Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 14.1.1. GCC Countries 14.1.2. South Africa 14.1.3. Rest of Middle East & Africa 14.2. Middle East & Africa Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 14.3. Middle East & Africa Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 14.3.1. Adult Patients 14.3.2. Pediatric Patients 14.4. Middle East & Africa Valganciclovir Market Value Share Analysis, by Application, 2021–2031 14.5. Middle East & Africa Valganciclovir Market Value Forecast, by Application, 2017–2031 14.5.1. Organ Transplant 14.5.2. Cytomegalovirus Retinitis 14.6. Middle East & Africa Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 14.7. Middle East & Africa Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 14.7.1. Hospital Pharmacies 14.7.2. Retail Pharmacies 14.8. Middle East & Africa Valganciclovir Market Attractiveness Analysis (2022–2031) 14.8.1. By Country/Sub-region 14.8.2. By Patient Age Group 14.8.3. By Application 14.8.4. By Distribution Channel 15. Competition Landscape 15.1. Competition Matrix 15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 15.2.1. Endo International plc (HQ, Business Segments, Employee Strength) 15.2.1.1. Company Details 15.2.1.2. Company Description 15.2.1.3. Business Overview 15.2.1.4. SWOT Analysis 15.2.1.5. Financial Analysis 15.2.1.6. Strategic Overview 15.2.2. Dr. Reddy's Laboratories AG (HQ, Business Segments, Employee Strength) 15.2.2.1. Company Details 15.2.2.2. Company Description 15.2.2.3. Business Overview 15.2.2.4. SWOT Analysis 15.2.2.5. Strategic Overview 15.2.3. F. Hoffmann-La Roche AG (HQ, Business Segments, Employee Strength) 15.2.3.1. Company Details 15.2.3.2. Company Description 15.2.3.3. Business Overview 15.2.3.4. SWOT Analysis 15.2.3.5. Strategic Overview 15.2.4. Cipla Limited (HQ, Business Segments, Employee Strength) 15.2.4.1. Company Details 15.2.4.2. Company Description 15.2.4.3. Business Overview 15.2.4.4. SWOT Analysis 15.2.4.5. Strategic Overview 15.2.5. Alniche Life Sciences Pvt. Ltd. (HQ, Business Segments, Employee Strength) 15.2.5.1. Company Details 15.2.5.2. Company Description 15.2.5.3. Business Overview 15.2.5.4. SWOT Analysis 15.2.5.5. Financial Analysis 15.2.5.6. Strategic Overview 15.2.6. Anthem Biosciences Private Limited (HQ, Business Segments, Employee Strength) 15.2.6.1. Company Details 15.2.6.2. Company Description 15.2.6.3. Business Overview 15.2.6.4. SWOT Analysis 15.2.6.5. Financial Analysis 15.2.6.6. Strategic Overview 15.2.7. Merck & Co., Inc. (HQ, Business Segments, Employee Strength) 15.2.7.1. Company Details 15.2.7.2. Company Description 15.2.7.3. Business Overview 15.2.7.4. SWOT Analysis 15.2.7.5. Financial Analysis 15.2.7.6. Strategic Overview 15.2.8. Panacea Biotec Ltd. (HQ, Business Segments, Employee Strength) 15.2.8.1. Company Details 15.2.8.2. Company Description 15.2.8.3. Business Overview 15.2.8.4. SWOT Analysis 15.2.8.5. Financial Analysis 15.2.8.6. Strategic Overview 15.2.9. Camber Pharmaceuticals, Inc. (HQ, Business Segments, Employee Strength) 15.2.9.1. Company Details 15.2.9.2. Company Description 15.2.9.3. Business Overview 15.2.9.4. SWOT Analysis 15.2.9.5. Financial Analysis 15.2.9.6. Strategic Overview 15.2.10. Healthiza Lifescience Private Limited (HQ, Business Segments, Employee Strength) 15.2.10.1. Company Details 15.2.10.2. Company Description 15.2.10.3. Business Overview 15.2.10.4. SWOT Analysis 15.2.10.5. Financial Analysis 15.2.10.6. Strategic Overview 図表リストList of TablesTable 01: Global Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 02: Global Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 04: Global Valganciclovir Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 05: North America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 06: North America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 07: North America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 08: North America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 09: Europe Valganciclovir Market Revenue (US$ Mn) Forecast, by Country,/Sub-region, 2017–2031 Table 10: Europe Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 11: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 12: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Asia Pacific Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 14: Asia Pacific Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 15: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 16: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Latin America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 18: Latin America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 19: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 20: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Middle East & Africa Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 22: Middle East & Africa Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 23: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 24: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
SummaryValganciclovir Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Valganciclovir Market 4. Market Overview 4.1. Introduction 4.1.1. Patient Age Group 4.1.2. Overview 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.3. Global Valganciclovir Market Analysis and Forecast, 2017–2031 4.3.1. Global Valganciclovir Market Revenue Projection (US$ Mn) 5. Market Outlook 5.1. Valganciclovir Virus Disease Prevalence 5.2. Key Industry Development 5.3. COVID-19 Impact Analysis 6. Global Valganciclovir Market Analysis and Forecast, by Patient Age Group 6.1. Key Findings/Developments 6.2. Introduction & Definition 6.3. Global Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 6.3.1. Adult Patients 6.3.2. Pediatric Patients 6.4. Global Valganciclovir Market Attractiveness Analysis, by Patient Age Group 7. Global Valganciclovir Market Analysis and Forecast, by Application 7.1. Key Findings/Developments 7.2. Introduction & Definition 7.3. Global Valganciclovir Market Value Forecast, by Application, 2017–2031 7.3.1. Organ Transplant 7.3.2. Cytomegalovirus Retinitis 7.4. Global Valganciclovir Market Attractiveness Analysis, by Application 8. Global Valganciclovir Market Analysis and Forecast, by Distribution Channel 8.1. Key Findings/Developments 8.2. Introduction & Definition 8.3. Global Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.4. Global Valganciclovir Market Attractiveness Analysis, by Distribution Channel 9. Global Valganciclovir Market Analysis and Forecast, by Region 9.1. Geographical Representation 9.2. Global Valganciclovir Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Global Valganciclovir Market Attractiveness Analysis, by Region 10. North America Valganciclovir Market Analysis and Forecast 10.1. North America Valganciclovir Market Value Share Analysis, by Country, 2017–2031 10.2. North America Valganciclovir Market Value Forecast, by Country, 2017–2031 10.2.1. U.S. 10.2.2. Canada 10.3. North America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 10.4. North America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 10.4.1. Adult Patients 10.4.2. Pediatric Patients 10.5. North America Valganciclovir Market Value Share Analysis, by Application, 2021–2031 10.6. North America Valganciclovir Market Value Forecast, by Application, 2017–2031 10.6.1. Organ Transplant 10.6.2. Cytomegalovirus Retinitis 10.7. North America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 10.8. North America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 10.8.1. Hospital Pharmacies 10.8.2. Retail Pharmacies 10.9. North America Valganciclovir Market Attractiveness Analysis (2022–2031) 10.9.1. By Country 10.9.2. By Patient Age Group 10.9.3. By Application 10.9.4. By Distribution Channel 11. Europe Valganciclovir Market Analysis and Forecast 11.1. Europe Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 11.1.1. Germany 11.1.2. France 11.1.3. U.K. 11.1.4. Spain 11.1.5. Italy 11.1.6. Rest of Europe 11.2. Europe Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 11.3. Europe Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 11.3.1. Adult Patients 11.3.2. Pediatric Patients 11.4. Europe Valganciclovir Market Value Share Analysis, by Application, 2021–2031 11.5. Europe Valganciclovir Market Value Forecast, by Application, 2017–2031 11.5.1. Organ Transplant 11.5.2. Cytomegalovirus Retinitis 11.6. Europe Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 11.7. Europe Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 11.7.1. Hospital Pharmacies 11.7.2. Retail Pharmacies 11.8. Europe Valganciclovir Market Attractiveness Analysis (2022–2031) 11.8.1. By Country/Sub-region 11.8.2. By Patient Age Group 11.8.3. By Application 11.8.4. By Distribution Channel 12. Asia Pacific Valganciclovir Market Analysis and Forecast 12.1. Asia Pacific Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 12.1.1. China 12.1.2. Japan 12.1.3. India 12.1.4. Australia & New Zealand 12.1.5. Rest of Asia Pacific 12.2. Asia Pacific Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 12.3. Asia Pacific Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 12.3.1. Adult Patients 12.3.2. Pediatric Patients 12.4. Asia Pacific Valganciclovir Market Value Share Analysis, by Application, 2021–2031 12.5. Asia Pacific Valganciclovir Market Value Forecast, by Application, 2017–2031 12.5.1. Organ Transplant 12.5.2. Cytomegalovirus Retinitis 12.6. Asia Pacific Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 12.7. Asia Pacific Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 12.7.1. Hospital Pharmacies 12.7.2. Retail Pharmacies 12.8. Asia Pacific Valganciclovir Market Attractiveness Analysis (2022–2031) 12.8.1. By Country/Sub-region 12.8.2. By Patient Age Group 12.8.3. By Application 12.8.4. By Distribution Channel 13. Latin America Valganciclovir Market Analysis and Forecast 13.1. Latin America Valganciclovir Market Value Forecast, by Country/Sub-region, 2017-2027 13.1.1. Brazil 13.1.2. Mexico 13.1.3. Rest of Latin America 13.2. Latin America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 13.3. Latin America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 13.3.1. Adult Patients 13.3.2. Pediatric Patients 13.4. Latin America Valganciclovir Market Value Share Analysis, by Application, 2021–2031 13.5. Latin America Valganciclovir Market Value Forecast, by Application, 2017–2031 13.5.1. Organ Transplant 13.5.2. Cytomegalovirus Retinitis 13.6. Latin America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 13.7. Latin America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 13.7.1. Hospital Pharmacies 13.8. Latin America Valganciclovir Market Attractiveness Analysis (2022–2031) 13.8.1. By Country/Sub-region 13.8.2. By Patient Age Group 13.8.3. By Application 13.8.4. By Distribution Channel 14. Middle East & Africa Valganciclovir Market Analysis and Forecast 14.1. Middle East & Africa Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031 14.1.1. GCC Countries 14.1.2. South Africa 14.1.3. Rest of Middle East & Africa 14.2. Middle East & Africa Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031 14.3. Middle East & Africa Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031 14.3.1. Adult Patients 14.3.2. Pediatric Patients 14.4. Middle East & Africa Valganciclovir Market Value Share Analysis, by Application, 2021–2031 14.5. Middle East & Africa Valganciclovir Market Value Forecast, by Application, 2017–2031 14.5.1. Organ Transplant 14.5.2. Cytomegalovirus Retinitis 14.6. Middle East & Africa Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031 14.7. Middle East & Africa Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031 14.7.1. Hospital Pharmacies 14.7.2. Retail Pharmacies 14.8. Middle East & Africa Valganciclovir Market Attractiveness Analysis (2022–2031) 14.8.1. By Country/Sub-region 14.8.2. By Patient Age Group 14.8.3. By Application 14.8.4. By Distribution Channel 15. Competition Landscape 15.1. Competition Matrix 15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 15.2.1. Endo International plc (HQ, Business Segments, Employee Strength) 15.2.1.1. Company Details 15.2.1.2. Company Description 15.2.1.3. Business Overview 15.2.1.4. SWOT Analysis 15.2.1.5. Financial Analysis 15.2.1.6. Strategic Overview 15.2.2. Dr. Reddy's Laboratories AG (HQ, Business Segments, Employee Strength) 15.2.2.1. Company Details 15.2.2.2. Company Description 15.2.2.3. Business Overview 15.2.2.4. SWOT Analysis 15.2.2.5. Strategic Overview 15.2.3. F. Hoffmann-La Roche AG (HQ, Business Segments, Employee Strength) 15.2.3.1. Company Details 15.2.3.2. Company Description 15.2.3.3. Business Overview 15.2.3.4. SWOT Analysis 15.2.3.5. Strategic Overview 15.2.4. Cipla Limited (HQ, Business Segments, Employee Strength) 15.2.4.1. Company Details 15.2.4.2. Company Description 15.2.4.3. Business Overview 15.2.4.4. SWOT Analysis 15.2.4.5. Strategic Overview 15.2.5. Alniche Life Sciences Pvt. Ltd. (HQ, Business Segments, Employee Strength) 15.2.5.1. Company Details 15.2.5.2. Company Description 15.2.5.3. Business Overview 15.2.5.4. SWOT Analysis 15.2.5.5. Financial Analysis 15.2.5.6. Strategic Overview 15.2.6. Anthem Biosciences Private Limited (HQ, Business Segments, Employee Strength) 15.2.6.1. Company Details 15.2.6.2. Company Description 15.2.6.3. Business Overview 15.2.6.4. SWOT Analysis 15.2.6.5. Financial Analysis 15.2.6.6. Strategic Overview 15.2.7. Merck & Co., Inc. (HQ, Business Segments, Employee Strength) 15.2.7.1. Company Details 15.2.7.2. Company Description 15.2.7.3. Business Overview 15.2.7.4. SWOT Analysis 15.2.7.5. Financial Analysis 15.2.7.6. Strategic Overview 15.2.8. Panacea Biotec Ltd. (HQ, Business Segments, Employee Strength) 15.2.8.1. Company Details 15.2.8.2. Company Description 15.2.8.3. Business Overview 15.2.8.4. SWOT Analysis 15.2.8.5. Financial Analysis 15.2.8.6. Strategic Overview 15.2.9. Camber Pharmaceuticals, Inc. (HQ, Business Segments, Employee Strength) 15.2.9.1. Company Details 15.2.9.2. Company Description 15.2.9.3. Business Overview 15.2.9.4. SWOT Analysis 15.2.9.5. Financial Analysis 15.2.9.6. Strategic Overview 15.2.10. Healthiza Lifescience Private Limited (HQ, Business Segments, Employee Strength) 15.2.10.1. Company Details 15.2.10.2. Company Description 15.2.10.3. Business Overview 15.2.10.4. SWOT Analysis 15.2.10.5. Financial Analysis 15.2.10.6. Strategic Overview List of Tables/GraphsList of TablesTable 01: Global Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 02: Global Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 04: Global Valganciclovir Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 05: North America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 06: North America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 07: North America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 08: North America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 09: Europe Valganciclovir Market Revenue (US$ Mn) Forecast, by Country,/Sub-region, 2017–2031 Table 10: Europe Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 11: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 12: Europe Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 13: Asia Pacific Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 14: Asia Pacific Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 15: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 16: Asia Pacific Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 17: Latin America Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 18: Latin America Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 19: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 20: Latin America Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 21: Middle East & Africa Valganciclovir Market Revenue (US$ Mn) Forecast, by Country, 2017–2031 Table 22: Middle East & Africa Valganciclovir Market Value (US$ Mn) Forecast, by Patient Age Group, 2017–2031 Table 23: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Application, 2017–2031 Table 24: Middle East & Africa Valganciclovir Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Transparency Market Research社の医療分野での最新刊レポート
本レポートと同じKEY WORD(organ)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|